Introducing Omnipod GO™
Who is Omnipod GO for?
Meet Joyce†
History with type 2 diabetes
- 48 years old
- 7-year history of type 2 diabetes
- A1c 9.0, fasting BG 172 mg/dL
- Metformin 1000 mg bid
- Semaglutide 2 mg once weekly
- During her last visit her healthcare provider recommended long-acting insulin, but she is hesitant to commit to daily injections.
- The healthcare provider needs a new way to introduce insulin therapy.
Glucose report
- Time Above Range (>180 mg/dL) 73%
- Time In Range (70-180 mg/dL) 27%
- Time Below Range (<70 mg/dL) 0%
How is Omnipod GO different than traditional type 2 insulin initiation?
✔ Controlled Dosing
Available in 7 different pre-programmed insulin doses. No settings or smartphone applications.
✔ Replaces Long-Acting Insulin Injections
Omnipod GO uses U-100 rapid-acting insulin to deliver microdoses over the course of 72 hours.
✔ Automatic Cannula Insertion
Users will not have to see or handle an insertion needle.
Get To Know Omnipod GO
Omnipod GO’s innovative, wearable, and continuous insulin delivery is designed to initiate insulin for people living with type 2 diabetes.
- Small, discreet & waterproof*
- Patient never sees or handle an injection needle
- Communicates through lights & sounds
- No separate insertion or controller device
*The Pod has an IP28 rating for up to 25 feet for 60 minutes.
FILL, PLACE, GO!
Omnipod GO was designed with simplicity in mind. Just fill the Pod, place it on your body and get on with your day. For additional instructions for use, see the videos and guides in the helpful resources below.
Fill
Fill the included syringe to the "Fill Here" line using a compatible U-100 rapid-acting insulin. Listen for the two beeps - Pod fill is complete.
Place
When the Pod shows a blinking amber light, you have 3 minutes to apply the Pod on your body. See below for Pod placement options.
GO
Once the Pod shows a blinking green light you are ready to GO.
How to Prescribe Omnipod GO
Start Omnipod GO in-clinic with the 30-day Sample Kit
Contents
- 1 box of 10 U Pods (5 Pods) for 15 days
- 1 box of 15 U Pods (5 Pods) for 15 days
- User Quick Start Guide and User Guide
A separate prescription of rapid-acting U-100 insulin vials (NovoLog®, Fiasp®, Humalog®, Admelog®, or Lyumjev®) is required to fill the Pod:
- 10 U/day, 15 U/day, 20 U/day, 25 U/day Omnipod GO Pods require 1 vial of U-100 insulin per month
- 30 U/day, 35 U/day and 40 U/day Omnipod GO Pods require 2 vials of U-100 insulin per month
Continue Omnipod GO
After patient uses the 30-day Sample Kit, prescribe a daily insulin dose that meets your patient’s daily insulin needs.
Pods are available in 5-packs of the following daily insulin amounts.
Titrate Omnipod GO
Titrate in increments of 5-units per day as needed.
Patients should monitor Fasting Blood Glucose (FBG) values and report readings:
| Fasting Blood Glucose | Patient Daily Insulin Adjustment* |
| Below Target | Consider decreasing the daily dose |
| Above Target | Consider increasing the daily dose |
| Within Target | No change: patient has reached maintenance dose |
* All dose adjustments should be individualized and dependent on glucose values as assessed by prescriber.
Additional Dosing Considerations
- When selecting a basal dose option, healthcare professionals should refer to their own experience when initiating continuous subcutaneous insulin infusion therapy with a patient as well as refer to professional guidelines for insulin therapy.1
- For patients already using insulin, healthcare professionals may consider reducing the prescribed daily insulin rate when transitioning to Omnipod GO Pods.1
- A person-centered approach should guide the choice of concomitant pharmacologic agents. Consider the effects on cardiovascular and renal comorbidities, efficacy, hypoglycemia risk, impact on weight, cost and access, risk for side effects, and individual preferences.2
- Patients should monitor fasting glucose values at a minimum and report readings to their healthcare team. Patients should monitor for hypoglycemia and report hypoglycemia to their healthcare team immediately. If unexplained hypoglycemia occurs, consider a dose reduction.1, 2
- If basal insulin has been titrated to an acceptable fasting blood glucose level (or if the dose is >0.5 units/kg/day with indications of need for other therapy) and A1C remains above target, reevaluate to further individualize therapy.2
- Patients should be educated that they must always respond to a red or blinking red Pod light. A red or blinking red Pod light indicates that insulin delivery has stopped and the Pod must be changed to continue receiving insulin. Failure to respond could result in the under-delivery of insulin which can lead to hyperglycemia.1
- Patients should be educated on a backup plan for basal insulin delivery should they experience an interruption in supplies.2
References
1 User Guide
2 ADA Standards of Medical Care in Diabetes 2023
Helpful Resources
Frequently Asked Questions:
When is Omnipod GO going to be available?
How long will the Limited Market Release be?
Can I or my patient participate in Limited Market Release?
Can my patients get a Sample Kit through the Pharmacy?
What is the difference between Omnipod GO and the other Omnipod® products?
Are the Omnipod GO Pods similar to your other devices like Omnipod DASH® or Omnipod® 5?
Is Omnipod GO approved for use with U-200 or U-500 insulin?
Who do my patients call if they have a problem with their Omnipod GO?
Omnipod GO Insulin Delivery Device
Omnipod GO is intended for the subcutaneous infusion of insulin at a preset basal rate in one 24-hour time period for 3 days (72 hours) in adults with type 2 diabetes. The Omnipod GO System has been tested and found to be safe for use with the following U-100 insulin: Fiasp®, Novolog®, Humalog®, Lyumjev®, and Admelog®. Refer to the Omnipod GO User Guide for complete safety information including indications, contraindications, warnings, cautions, and instructions.